Comparing the current results to its competitors, Assembly Biosciences Inc reported Revenue decrease in the 1 quarter 2026 year on year by -12.8 %, despite the revenue increase by the most of its competitors of 17.35 %, recorded in the same quarter.
Assembly Biosciences Inc , slower than the average decrease reported by the company's competitors of -43.58 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -43.58 %
Assembly Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical and biotechnology industry, which is characterized by rapid technological advancements and innovation. It faces competition from various entities developing and commercializing products that compete with its drug candidates. Competitors include large pharmaceutical companies and smaller biotechnology firms such as GlaxoSmithKline plc, Enanta Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Vir Bio, Mirum Pharmaceuticals, Huahui Health, Aligos Therapeutics, Innovative Molecules, and AiCuris Anti-infective Cures AG, the latter being part of Asahi Kasei following its pending acquisition of AiCuris. Additional competition may arise from existing hepatitis B virus (HBV) treatments, as well as academic institutions, government agencies, and other public and private research organizations engaged in similar research, development, manufacturing, and commercialization activities.
October 10, 2025
Advancements and Challenges: Assembly Biosciences’ Phase 1b Data for ABI-5366 and Market Dynamics In recent developments within the biotechnology realm, Assembly Biosciences Inc. has made significant strides with their novel therapeutic candidate, ABI-5366, aimed at combating recurrent genital herpes. The interim Phase 1b data for ABI-5366, a helicase-primase inhibitor, was revealed at the prestigious 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)-Europe. This late-breaking oral presentation offered fresh insights into the drug s potential, complementing earlier data released this year for two patient cohorts with recurrent genital herpes. Meanwhile, on the financi...
September 23, 2024
Advances in Hepatitis B and Herpes Simplex Virus Therapeutics: Assembly Biosciences Promising Trials Assembly Biosciences has made significant progress in its clinical development pipeline for antiviral therapies targeting chronic hepatitis B virus (HBV) infection and herpes simplex virus (HSV). Recent reports highlight promising interim results from the Phase 1a clinical trial of the long-acting helicase-primase inhibitor candidate, ABI-5366, and the initiation of Phase 1b studies evaluating the next-generation capsid assembly modulator candidate, ABI-4334. The collective data from these studies suggest a favorable safety profile and an encouraging path forward for these therapies. Phase 1a Results for AB...
July 15, 2024
Assembly Biosciences, a leading biotechnology company focused on developing innovative treatments for viral infections, recently presented new preclinical data at the International Herpesvirus Workshop. The data showcased the potential of their investigational helicase-primase inhibitors, ABI-5366 and ABI-1179, as promising candidates for the treatment of recurrent genital herpes.Herpes simplex virus type 2 (HSV-2) is a prevalent sexually transmitted infection that affects millions of people worldwide. The current treatment options for recurrent genital herpes are limited and predominantly involve the use of antiviral medications, which only provide temporary relief and do not offer a cure. Assembly Bioscien...
June 10, 2024
Assembly Biosciences, a clinical-stage biotechnology company, has recently announced the dosing of the first participant in a Phase 1a/b clinical trial for their herpes simplex virus (HSV) helicase-primase inhibitor candidate, ABI-5366. This marks an important milestone in the development of a potential treatment for HSV infections.The Phase 1a study aims to evaluate the safety, tolerability, and pharmacokinetics of ABI-5366 in healthy participants. The trial will use a single ascending dosing strategy to determine the optimal dose for further investigation. Interim data from this study is expected to be available in the third quarter of 2024, providing valuable insights into the drug candidate s potential e...
June 5, 2024
Promising Preclinical Data for Hepatitis D Virus Entry Inhibitor ABI-6250 Presented at EASL Congress 2024 The treatment of Hepatitis D Virus (HDV) infection, one of the most severe forms of viral hepatitis, remains an area of significant unmet medical need. Current therapeutic options for HDV are limited and often fail to achieve sustained virological response. As bio-pharmaceutical companies strive to develop innovative solutions, Assembly Biosciences, Inc., a leader in the field of antiviral therapeutics, has unveiled promising preclinical data for their HDV entry inhibitor candidate, ABI-6250. This novel, orally bioavailable small molecule garnered attention at the European Association for the Study of t...
May 8, 2024
In recent reports emanating from the biotech sector, Assembly Biosciences, Inc. (Nasdaq: ASMB) disclosed their financial results for the first quarter of the year 2024, which wrapped up on March 31, 2024. Operating from South San Francisco, California, ASMB is primarily engaged in engineering contemporary therapeutics targeted at grappling with severe viral diseases. On the frontline, Assembly Biosciences is known for offering innovative hisses that confront the challenging bio-health environment, especially in the realm of severe viral diseases. By unveiling their Q1 2024 financial results, Assembly Biosciences is providing investors, stakeholders, and the scientific community an in-depth insight into the c...
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Sources:
Assembly Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Assembly Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
